Actavis, Inc. Stock Quote & Summary Data
Dynamic quotes: Off
|
ETFs with ACT as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 4.68% | SPDR S&P Pharmaceuticals ETF (XPH) | +11.99 (19.90%) |
| 3.62% | iShares Dow Jones U.S. Pharmaceutical Index Fund (IHE) | +12.92 (14.28%) |
| 1.98% | Guggenheim Mid-Cap Core ETF (CZA) | +4.41 (12.27%) |
| 1.1% | iShares Morningstar Mid Core Index Fund (JKG) | +9.96 (9.48%) |
| 0% | Direxion S&P 500 DRRC Volatility Response Shares (VSPY) | +5.04 (11.23%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
On October 31, 2012, Watson Pharmaceuticals, Inc. completed the acquisition of Actavis Group. Watson Pharmaceuticals, Inc. common stock was traded on the New York Stock Exchange under the symbol “WPI” until close of trading on January 23, 2013, at which time Watson Pharmaceuticals, Inc. changed its corporate name to “Actavis, Inc.” and changed its ticker symbol to “ACT.” Actavis, Inc. (“Actavis,” the “Company,” “we,” “us,” or “our”) is a leading integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (“OTC”) pharmaceutical products. We also develop and out-license generic pharmaceutical products primarily in Europe through our Medis third-party business. Following the renaming, the Company also changed the name of its three reporting segments. ... More ...
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $6 |
| Quarterly EPS Est: | 1.99 |
| PEG Ratio: | 1.20 |
|
Mean Recommendation: View Summary / View All |
1.71 |
Data is provided by Zacks Investment Research